← All trials
NCT04688034
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Dec 29, 2020
- Last posted
- Dec 29, 2020
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tokyo Metropolitan Komagome HospitalLead sponsor
- Tokyo Metropolitan Komagome HospitalOverall official - principal investigator
- Tokyo Metropolitan Komagome HospitalSponsor investigator
- Japan Agency for Medical Research and DevelopmentCollaborator
- OHARA Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.